ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Sesamol as a multifunctional antioxidant in tissue injury and repair: mechanistic insights and therapeutic perspectives.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tissue injury results from cellular or structural disruption caused by physical, chemical, or biological insults, often accompanied by oxidative stress and inflammation. Reactive oxygen species (ROS) play a dual role in tissue homeostasis, supporting repair at physiological levels but causing damage when overproduced. Among natural antioxidants, sesamol, a phenolic lignan derived from Sesamum indicum oil, has demonstrated potent free radical scavenging, anti-inflammatory, and cytoprotective effects. This review aims to comprehensively examine the therapeutic potential of sesamol in mitigating tissue injury and promoting tissue repair. It is the first integrative review linking pharmacokinetics, toxicology, and pharmacodynamics of sesamol in tissue repair while emphasizing recent advances in pharmaceutical formulations that enhance its clinical applicability. An extensive literature survey was conducted using databases such as PubMed, Scopus, and Web of Science, covering studies from 1990 to 2025. Relevant preclinical and clinical reports were critically analyzed to summarize sesamol's biochemical mechanisms, pharmacokinetics, toxicity, and formulation strategies in various tissue injury models, including endotoxin, ischemia-reperfusion, radiation, chemical, and wound-induced injuries. Sesamol exhibits broad-spectrum protective activity through modulation of oxidative stress, inflammatory, and apoptotic pathways. It reduces ROS, MDA, and proinflammatory cytokines (TNF-α, ILs, NF-κB) while enhancing antioxidant enzymes (SOD, CAT, GPx, Nrf2) and pro-healing factors (VEGF, PDGF, TGF-β). Despite favorable solubility and oral bioavailability, sesamol's rapid metabolism limits its systemic exposure. Nanoformulations, such as solid lipid nanoparticles, PLGA nanosuspensions, and nanofiber dressings, have shown enhanced stability, sustained release, tissue retention, and superior wound-healing efficacy, in vivo. Sesamol is a multitarget natural antioxidant with significant promise in tissue repair and regeneration. Pharmaceutical encapsulation strategies offer a viable route to overcome its physicochemical limitations and translate its potent redox-modulating and regenerative properties into clinically relevant therapies for wound and organ protection.
Indexed as
Identifiers
41770367What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.